Factors such as increase in awareness of hepatitis B infection prevention, governments have mandated the immunization and hepatitis B vaccine included in national immunization schedule in many countries driving the market growth of hepatitis B vaccine globally.
The report titled Hepatitis B Vaccine Market - Growth, Future Prospects and Competitive Analysis, 2022 - 2030; offers strategic insights into the overall hepatitis B vaccine market along with the market size and estimates for the duration 2020 to 2030. The research study covers in-depth analysis of market segments based on composition, end users age and different geographical regions.
Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global hepatitis B vaccine market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global hepatitis B vaccine market. This report concludes with company profiles section that highlights major information about the key players engaged in global hepatitis B vaccine market. In-depth competitive environment analysis and historical years (2020) market size data are also provided in the report.
Hepatitis B is life threatening liver disease that can cause acute and chronic liver infection and may lead to cirrhosis and liver cancer. Safe and effective vaccines are available in market to prevent hepatitis B infection. According to World Health Organization (WHO) prevalence of hepatitis B is highest in Western Pacific and in African region more than 6% of the adult population is affected with hepatitis B infection. In South East Asia and European region, it is estimated that 2% and 1.6% of the general population is affected with hepatitis B, respectively. The burden of hepatitis B infection is considerably less in the American population which is approximately 0.7% of the overall population. It is observed that in the base year 2021, North America was major revenue contributing segment. Factors such as higher cost of vaccines, immunization programs and favorable R&D activities driving the market growth in North America. Currently, Asia Pacific is not major revenue generating segment but it is estimated that it will show highest CAGR during forecast period. Rising healthcare awareness, populous countries, increase in awareness of vaccines, government initiative in vaccination program would influence the growth of hepatitis B vaccine market in Asia Pacific region.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
This product will be delivered within 2 business days.
The report titled Hepatitis B Vaccine Market - Growth, Future Prospects and Competitive Analysis, 2022 - 2030; offers strategic insights into the overall hepatitis B vaccine market along with the market size and estimates for the duration 2020 to 2030. The research study covers in-depth analysis of market segments based on composition, end users age and different geographical regions.
Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global hepatitis B vaccine market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global hepatitis B vaccine market. This report concludes with company profiles section that highlights major information about the key players engaged in global hepatitis B vaccine market. In-depth competitive environment analysis and historical years (2020) market size data are also provided in the report.
Composition analysis:
Hepatitis B is a life threatening liver infection caused by the hepatitis B virus. Vaccine is most effective than any other treatment in preventing infection. According to WHO (world health organization), prevalence of hepatitis B is highest in Western Pacific and African region however, lowest in American population. Factors such as an increase in awareness of vaccines are expected to contribute the market growth of hepatitis B vaccine globally. For the purpose of study market is segmented on the basis of composition of vaccine such as mono and combination vaccine. Combination vaccines that protect against multiple pathogens, it involves combination of multiple antigens into a single vaccine. Combination vaccine such as Infanrix Hexa, Hexaci ma/Hexyon, Twinrix, Ambirix, Comvax widely used for the prevention of hepatitis B infection. It is observed that, combination vaccine is major revenue generating segment. Factors such as higher patient compliance, reduced number of dose frequency, better disease control, coverage of vaccine under national immunization program and reduced chances of missing immunization are driving the growth of combination vaccine market globally. It is observed that mono vaccines such as Recombi vax HB, Fendrix and Engeri x-B are approved for the treatment of hepatitis B infection.End user age group analysis:
Hepatitis B virus cause life threatening liver disease, vaccine is more effective than any other treatment in preventing infection. The choice of hepatitis B vaccine varies with the age. Adult Hepatitis B Vaccines are used for active immunization of individuals aged above 18 and 21 in Europe and US respectively. Hepatitis B is one of the most common travelers diseases which can be avoided by vaccine immunization. Governments across the world have mandated the immunization of travelers, which is acting as a growth driver for the hepatitis B vaccines market across the world. It is observed that in base 2016, adult hepatitis B vaccines held largest market share as adults have high risk of developing hepatitis B infections due to end-stage renal disease, drug abuse and HIV infection which is driving the market growth of adult hepatitis B vaccines globally. In terms of immunogenicity, pediatric vaccines differ from adult vaccines. Pediatric hepatitis B vaccines are used for the prevention of hepatitis B infection in infants, toddlers, and adolescents because babies and young children are at higher risk for developing the potentially fatal complications of the infection. It is estimated that pediatric hepatitis B vaccines will show steady growth rate during forecast period. It is observed that pediatric vaccines such Infanrix, hexa, Hexacima/Hexyon, Ambirix, and Comvax. Infanrix hexa are widely accepted in market.Hepatitis B is life threatening liver disease that can cause acute and chronic liver infection and may lead to cirrhosis and liver cancer. Safe and effective vaccines are available in market to prevent hepatitis B infection. According to World Health Organization (WHO) prevalence of hepatitis B is highest in Western Pacific and in African region more than 6% of the adult population is affected with hepatitis B infection. In South East Asia and European region, it is estimated that 2% and 1.6% of the general population is affected with hepatitis B, respectively. The burden of hepatitis B infection is considerably less in the American population which is approximately 0.7% of the overall population. It is observed that in the base year 2021, North America was major revenue contributing segment. Factors such as higher cost of vaccines, immunization programs and favorable R&D activities driving the market growth in North America. Currently, Asia Pacific is not major revenue generating segment but it is estimated that it will show highest CAGR during forecast period. Rising healthcare awareness, populous countries, increase in awareness of vaccines, government initiative in vaccination program would influence the growth of hepatitis B vaccine market in Asia Pacific region.
Historical & Forecast Period
This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Hepatitis B Vaccine market are as follows:- Research and development budgets of manufacturers and government spending
- Revenues of key companies in the market segment
- Number of end users and consumption volume, price and value.
- Geographical revenues generate by countries considered in the report
- Micro and macro environment factors that are currently influencing the Hepatitis B Vaccine market and their expected impact during the forecast period.
Market Segmentation
Composition
- Combination Vaccines
- Mono Vaccines
End Users Age
- Adult Hepatitis B vaccines
- Paediatric Hepatitis B vaccines
Key questions answered in this report
- What are the key micro and macro environmental factors that are impacting the growth of Hepatitis B Vaccine market?
- What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
- Estimated forecast and market projections up to 2030.
- Which segment accounts for the fastest CAGR during the forecast period?
- Which market segment holds a larger market share and why?
- Are low and middle-income economies investing in the Hepatitis B Vaccine market?
- Which is the largest regional market for Hepatitis B Vaccine market?
- What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
- Which are the key trends driving Hepatitis B Vaccine market growth?
- Who are the key competitors and what are their key strategies to enhance their market presence in the Hepatitis B Vaccine market worldwide?
This product will be delivered within 2 business days.
Table of Contents
1. Preface1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted
2. Executive Summary
2.1. Market Snapshot: Global Hepatitis B Vaccine Market
2.2. Global Hepatitis B Vaccine Market, By Composition, 2021 (US$ Million)
2.3. Global Hepatitis B Vaccine Market, By End Users Age, 2021 (US$ Million)
2.4. Global Hepatitis B Vaccine Market, By Geography, 2021 (US$ Million)
2.5. Attractive Investment Proposition by Geography, 2021
3. Hepatitis B Vaccine Market: Competitive Analysis
3.1. Market Positioning of Key Hepatitis B Vaccine Market Vendors
3.2. Strategies Adopted by Hepatitis B Vaccine Market Vendors
3.3. Key Industry Strategies
3.4. Tier Analysis 2021 Versus 2030
4. Hepatitis B Vaccine Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Hepatitis B Vaccine Market Value, 2020 - 2030, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
5. Hepatitis B Vaccine Market: By Composition, 2020-2030, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2021 Versus 2030
5.3. Market Segmentation
5.3.1. Combination Vaccines
5.3.2. Mono Vaccines
6. Hepatitis B Vaccine Market: By End Users Age, 2020-2030, USD (Million)
6.1. Market Overview
6.2. Growth & Revenue Analysis: 2021 Versus 2030
6.3. Market Segmentation
6.3.1. Adult Hepatitis B vaccines
6.3.2. Paediatric Hepatitis B vaccines
7. North America Hepatitis B Vaccine Market, 2020-2030, USD (Million)
7.1. Market Overview
7.2. Hepatitis B Vaccine Market: By Composition, 2020-2030, USD (Million)
7.3. Hepatitis B Vaccine Market: By End Users Age, 2020-2030, USD (Million)
7.4.Hepatitis B Vaccine Market: By Region, 2020-2030, USD (Million)
7.4.1.North America
7.4.1.1. U.S.
7.4.1.1.1. Hepatitis B Vaccine Market: By Composition, 2020-2030, USD (Million)
7.4.1.1.1. Hepatitis B Vaccine Market: By End Users Age, 2020-2030, USD (Million)
7.4.1.2. Canada
7.4.1.2.1. Hepatitis B Vaccine Market: By Composition, 2020-2030, USD (Million)
7.4.1.2.1. Hepatitis B Vaccine Market: By End Users Age, 2020-2030, USD (Million)
7.4.1.3. Rest of North America
7.4.1.3.1. Hepatitis B Vaccine Market: By Composition, 2020-2030, USD (Million)
7.4.1.3.1. Hepatitis B Vaccine Market: By End Users Age, 2020-2030, USD (Million)
8. UK and European Union Hepatitis B Vaccine Market, 2020-2030, USD (Million)
8.1. Market Overview
8.2. Hepatitis B Vaccine Market: By Composition, 2020-2030, USD (Million)
8.3. Hepatitis B Vaccine Market: By End Users Age, 2020-2030, USD (Million)
8.4.Hepatitis B Vaccine Market: By Region, 2020-2030, USD (Million)
8.4.1.UK and European Union
8.4.1.1. UK
8.4.1.1.1. Hepatitis B Vaccine Market: By Composition, 2020-2030, USD (Million)
8.4.1.1.1. Hepatitis B Vaccine Market: By End Users Age, 2020-2030, USD (Million)
8.4.1.2. Germany
8.4.1.2.1. Hepatitis B Vaccine Market: By Composition, 2020-2030, USD (Million)
8.4.1.2.1. Hepatitis B Vaccine Market: By End Users Age, 2020-2030, USD (Million)
8.4.1.3. Spain
8.4.1.3.1. Hepatitis B Vaccine Market: By Composition, 2020-2030, USD (Million)
8.4.1.3.1. Hepatitis B Vaccine Market: By End Users Age, 2020-2030, USD (Million)
8.4.1.4. Italy
8.4.1.4.1. Hepatitis B Vaccine Market: By Composition, 2020-2030, USD (Million)
8.4.1.4.1. Hepatitis B Vaccine Market: By End Users Age, 2020-2030, USD (Million)
8.4.1.5. France
8.4.1.5.1. Hepatitis B Vaccine Market: By Composition, 2020-2030, USD (Million)
8.4.1.5.1. Hepatitis B Vaccine Market: By End Users Age, 2020-2030, USD (Million)
8.4.1.6. Rest of Europe
8.4.1.6.1. Hepatitis B Vaccine Market: By Composition, 2020-2030, USD (Million)
8.4.1.6.1. Hepatitis B Vaccine Market: By End Users Age, 2020-2030, USD (Million)
9. Asia Pacific Hepatitis B Vaccine Market, 2020-2030, USD (Million)
9.1. Market Overview
9.2. Hepatitis B Vaccine Market: By Composition, 2020-2030, USD (Million)
9.3. Hepatitis B Vaccine Market: By End Users Age, 2020-2030, USD (Million)
9.4.Hepatitis B Vaccine Market: By Region, 2020-2030, USD (Million)
9.4.1.Asia Pacific
9.4.1.1. China
9.4.1.1.1. Hepatitis B Vaccine Market: By Composition, 2020-2030, USD (Million)
9.4.1.1.1. Hepatitis B Vaccine Market: By End Users Age, 2020-2030, USD (Million)
9.4.1.2. Japan
9.4.1.2.1. Hepatitis B Vaccine Market: By Composition, 2020-2030, USD (Million)
9.4.1.2.1. Hepatitis B Vaccine Market: By End Users Age, 2020-2030, USD (Million)
9.4.1.3. India
9.4.1.3.1. Hepatitis B Vaccine Market: By Composition, 2020-2030, USD (Million)
9.4.1.3.1. Hepatitis B Vaccine Market: By End Users Age, 2020-2030, USD (Million)
9.4.1.4. Australia
9.4.1.4.1. Hepatitis B Vaccine Market: By Composition, 2020-2030, USD (Million)
9.4.1.4.1. Hepatitis B Vaccine Market: By End Users Age, 2020-2030, USD (Million)
9.4.1.5. South Korea
9.4.1.5.1. Hepatitis B Vaccine Market: By Composition, 2020-2030, USD (Million)
9.4.1.5.1. Hepatitis B Vaccine Market: By End Users Age, 2020-2030, USD (Million)
9.4.1.6. Rest of Asia Pacific
9.4.1.6.1. Hepatitis B Vaccine Market: By Composition, 2020-2030, USD (Million)
9.4.1.6.1. Hepatitis B Vaccine Market: By End Users Age, 2020-2030, USD (Million)
10. Latin America Hepatitis B Vaccine Market, 2020-2030, USD (Million)
10.1. Market Overview
10.2. Hepatitis B Vaccine Market: By Composition, 2020-2030, USD (Million)
10.3. Hepatitis B Vaccine Market: By End Users Age, 2020-2030, USD (Million)
10.4.Hepatitis B Vaccine Market: By Region, 2020-2030, USD (Million)
10.4.1.Latin America
10.4.1.1. Brazil
10.4.1.1.1. Hepatitis B Vaccine Market: By Composition, 2020-2030, USD (Million)
10.4.1.1.1. Hepatitis B Vaccine Market: By End Users Age, 2020-2030, USD (Million)
10.4.1.2. Mexico
10.4.1.2.1. Hepatitis B Vaccine Market: By Composition, 2020-2030, USD (Million)
10.4.1.2.1. Hepatitis B Vaccine Market: By End Users Age, 2020-2030, USD (Million)
10.4.1.3. Rest of Latin America
10.4.1.3.1. Hepatitis B Vaccine Market: By Composition, 2020-2030, USD (Million)
10.4.1.3.1. Hepatitis B Vaccine Market: By End Users Age, 2020-2030, USD (Million)
11. Middle East and Africa Hepatitis B Vaccine Market, 2020-2030, USD (Million)
11.1. Market Overview
11.2. Hepatitis B Vaccine Market: By Composition, 2020-2030, USD (Million)
11.3. Hepatitis B Vaccine Market: By End Users Age, 2020-2030, USD (Million)
11.4.Hepatitis B Vaccine Market: By Region, 2020-2030, USD (Million)
11.4.1.Middle East and Africa
11.4.1.1. GCC
11.4.1.1.1. Hepatitis B Vaccine Market: By Composition, 2020-2030, USD (Million)
11.4.1.1.1. Hepatitis B Vaccine Market: By End Users Age, 2020-2030, USD (Million)
11.4.1.2. Africa
11.4.1.2.1. Hepatitis B Vaccine Market: By Composition, 2020-2030, USD (Million)
11.4.1.2.1. Hepatitis B Vaccine Market: By End Users Age, 2020-2030, USD (Million)
11.4.1.3. Rest of Middle East and Africa
11.4.1.3.1. Hepatitis B Vaccine Market: By Composition, 2020-2030, USD (Million)
11.4.1.3.1. Hepatitis B Vaccine Market: By End Users Age, 2020-2030, USD (Million)
12. Company Profile
12.1. Beijing Minhai Biotechnology
12.1.1. Company Overview
12.1.2. Financial Performance
12.1.3. Product Portfolio
12.1.4. Strategic Initiatives
12.2. CSL Limited
12.2.1. Company Overview
12.2.2. Financial Performance
12.2.3. Product Portfolio
12.2.4. Strategic Initiatives
12.3. Dynavax Technologies
12.3.1. Company Overview
12.3.2. Financial Performance
12.3.3. Product Portfolio
12.3.4. Strategic Initiatives
12.4. Emergent Biosolutions
12.4.1. Company Overview
12.4.2. Financial Performance
12.4.3. Product Portfolio
12.4.4. Strategic Initiatives
12.5. GlaxoSmithKline Biologicals
12.5.1. Company Overview
12.5.2. Financial Performance
12.5.3. Product Portfolio
12.5.4. Strategic Initiatives
12.6. Merck & Co, Inc.
12.6.1. Company Overview
12.6.2. Financial Performance
12.6.3. Product Portfolio
12.6.4. Strategic Initiatives
12.7. Novartis AG
12.7.1. Company Overview
12.7.2. Financial Performance
12.7.3. Product Portfolio
12.7.4. Strategic Initiatives
12.8. Pfizer Inc.
12.8.1. Company Overview
12.8.2. Financial Performance
12.8.3. Product Portfolio
12.8.4. Strategic Initiatives
12.9. Sanofi Pasteur
12.9.1. Company Overview
12.9.2. Financial Performance
12.9.3. Product Portfolio
12.9.4. Strategic Initiatives
12.10. Serum Institute of India
12.10.1. Company Overview
12.10.2. Financial Performance
12.10.3. Product Portfolio
12.10.4. Strategic Initiatives
12.11. Sinovac Biotech
12.11.1. Company Overview
12.11.2. Financial Performance
12.11.3. Product Portfolio
12.11.4. Strategic Initiatives
List of Figures
Figure 1 Global Hepatitis B Vaccine Market: Market Coverage
Figure 2 Research Methodology and Data Sources
Figure 3 Market Size Estimation - Top Down & Bottom-Up Approach
Figure 4 Global Hepatitis B Vaccine Market: Quality Assurance
Figure 5 Global Hepatitis B Vaccine Market, By Composition, 2021
Figure 6 Global Hepatitis B Vaccine Market, By End Users Age, 2021
Figure 7 Global Hepatitis B Vaccine Market, By Geography, 2021
Figure 8 Market Geographical Opportunity Matrix - Global Hepatitis B Vaccine Market, 2021
Figure 9 Market Positioning of Key Hepatitis B Vaccine Market Players, 2021
Figure 10 Global Hepatitis B Vaccine Market - Tier Analysis - Percentage of Revenues by Tier Level, 2021 Versus 2030
Figure 11 Global Hepatitis B Vaccine Market, By Composition, 2021 Vs 2030, %
Figure 12 Global Hepatitis B Vaccine Market, By End Users Age, 2021 Vs 2030, %
Figure 13 U.S. Hepatitis B Vaccine Market (US$ Million), 2020 - 2030
Figure 14 Canada Hepatitis B Vaccine Market (US$ Million), 2020 - 2030
Figure 15 Rest of North America Hepatitis B Vaccine Market (US$ Million), 2020 - 2030
Figure 16 UK Hepatitis B Vaccine Market (US$ Million), 2020 - 2030
Figure 17 Germany Hepatitis B Vaccine Market (US$ Million), 2020 - 2030
Figure 18 Spain Hepatitis B Vaccine Market (US$ Million), 2020 - 2030
Figure 19 Italy Hepatitis B Vaccine Market (US$ Million), 2020 - 2030
Figure 20 France Hepatitis B Vaccine Market (US$ Million), 2020 - 2030
Figure 21 Rest of Europe Hepatitis B Vaccine Market (US$ Million), 2020 - 2030
Figure 22 China Hepatitis B Vaccine Market (US$ Million), 2020 - 2030
Figure 23 Japan Hepatitis B Vaccine Market (US$ Million), 2020 - 2030
Figure 24 India Hepatitis B Vaccine Market (US$ Million), 2020 - 2030
Figure 25 Australia Hepatitis B Vaccine Market (US$ Million), 2020 - 2030
Figure 26 South Korea Hepatitis B Vaccine Market (US$ Million), 2020 - 2030
Figure 27 Rest of Asia Hepatitis B Vaccine Market (US$ Million), 2020 - 2030
Figure 28 Brazil Hepatitis B Vaccine Market (US$ Million), 2020 - 2030
Figure 29 Mexico Hepatitis B Vaccine Market (US$ Million), 2020 - 2030
Figure 30 Rest of Latin America Hepatitis B Vaccine Market (US$ Million), 2020 - 2030
Figure 31 GCC Hepatitis B Vaccine Market (US$ Million), 2020 - 2030
Figure 32 Africa Hepatitis B Vaccine Market (US$ Million), 2020 - 2030
Figure 33 Rest of Middle East and Africa Hepatitis B Vaccine Market (US$ Million), 2020 - 2030
List of Tables
Table 1 Global Hepatitis B Vaccine Market By Composition, 2020-2030, USD (Million)
Table 2 Global Hepatitis B Vaccine Market By End Users Age, 2020-2030, USD (Million)
Table 3 North America Hepatitis B Vaccine Market By Composition, 2020-2030, USD (Million)
Table 4 North America Hepatitis B Vaccine Market By End Users Age, 2020-2030, USD (Million)
Table 5 U.S. Hepatitis B Vaccine Market By Composition, 2020-2030, USD (Million)
Table 6 U.S. Hepatitis B Vaccine Market By End Users Age, 2020-2030, USD (Million)
Table 7 Canada Hepatitis B Vaccine Market By Composition, 2020-2030, USD (Million)
Table 8 Canada Hepatitis B Vaccine Market By End Users Age, 2020-2030, USD (Million)
Table 9 Rest of North America Hepatitis B Vaccine Market By Composition, 2020-2030, USD (Million)
Table 10 Rest of North America Hepatitis B Vaccine Market By End Users Age, 2020-2030, USD (Million)
Table 11 UK and European Union Hepatitis B Vaccine Market By Composition, 2020-2030, USD (Million)
Table 12 UK and European Union Hepatitis B Vaccine Market By End Users Age, 2020-2030, USD (Million)
Table 13 UK Hepatitis B Vaccine Market By Composition, 2020-2030, USD (Million)
Table 14 UK Hepatitis B Vaccine Market By End Users Age, 2020-2030, USD (Million)
Table 15 Germany Hepatitis B Vaccine Market By Composition, 2020-2030, USD (Million)
Table 16 Germany Hepatitis B Vaccine Market By End Users Age, 2020-2030, USD (Million)
Table 17 Spain Hepatitis B Vaccine Market By Composition, 2020-2030, USD (Million)
Table 18 Spain Hepatitis B Vaccine Market By End Users Age, 2020-2030, USD (Million)
Table 19 Italy Hepatitis B Vaccine Market By Composition, 2020-2030, USD (Million)
Table 20 Italy Hepatitis B Vaccine Market By End Users Age, 2020-2030, USD (Million)
Table 21 France Hepatitis B Vaccine Market By Composition, 2020-2030, USD (Million)
Table 22 France Hepatitis B Vaccine Market By End Users Age, 2020-2030, USD (Million)
Table 23 Rest of Europe Hepatitis B Vaccine Market By Composition, 2020-2030, USD (Million)
Table 24 Rest of Europe Hepatitis B Vaccine Market By End Users Age, 2020-2030, USD (Million)
Table 25 Asia Hepatitis B Vaccine Market By Composition, 2020-2030, USD (Million)
Table 26 Asia Hepatitis B Vaccine Market By End Users Age, 2020-2030, USD (Million)
Table 27 China Hepatitis B Vaccine Market By Composition, 2020-2030, USD (Million)
Table 28 China Hepatitis B Vaccine Market By End Users Age, 2020-2030, USD (Million)
Table 29 Japan Hepatitis B Vaccine Market By Composition, 2020-2030, USD (Million)
Table 30 Japan Hepatitis B Vaccine Market By End Users Age, 2020-2030, USD (Million)
Table 31 India Hepatitis B Vaccine Market By Composition, 2020-2030, USD (Million)
Table 32 India Hepatitis B Vaccine Market By End Users Age, 2020-2030, USD (Million)
Table 33 Australia Hepatitis B Vaccine Market By Composition, 2020-2030, USD (Million)
Table 34 Australia Hepatitis B Vaccine Market By End Users Age, 2020-2030, USD (Million)
Table 35 South Korea Hepatitis B Vaccine Market By Composition, 2020-2030, USD (Million)
Table 36 South Korea Hepatitis B Vaccine Market By End Users Age, 2020-2030, USD (Million)
Table 37 Latin America Hepatitis B Vaccine Market By Composition, 2020-2030, USD (Million)
Table 38 Latin America Hepatitis B Vaccine Market By End Users Age, 2020-2030, USD (Million)
Table 39 Brazil Hepatitis B Vaccine Market By Composition, 2020-2030, USD (Million)
Table 40 Brazil Hepatitis B Vaccine Market By End Users Age, 2020-2030, USD (Million)
Table 41 Mexico Hepatitis B Vaccine Market By Composition, 2020-2030, USD (Million)
Table 42 Mexico Hepatitis B Vaccine Market By End Users Age, 2020-2030, USD (Million)
Table 43 Rest of Latin America Hepatitis B Vaccine Market By Composition, 2020-2030, USD (Million)
Table 44 Rest of Latin America Hepatitis B Vaccine Market By End Users Age, 2020-2030, USD (Million)
Table 45 Middle East and Africa Hepatitis B Vaccine Market By Composition, 2020-2030, USD (Million)
Table 46 Middle East and Africa Hepatitis B Vaccine Market By End Users Age, 2020-2030, USD (Million)
Table 47 GCC Hepatitis B Vaccine Market By Composition, 2020-2030, USD (Million)
Table 48 GCC Hepatitis B Vaccine Market By End Users Age, 2020-2030, USD (Million)
Table 49 Africa Hepatitis B Vaccine Market By Composition, 2020-2030, USD (Million)
Table 50 Africa Hepatitis B Vaccine Market By End Users Age, 2020-2030, USD (Million)
Table 51 Rest of Middle East and Africa Hepatitis B Vaccine Market By Composition, 2020-2030, USD (Million)
Table 52 Rest of Middle East and Africa Hepatitis B Vaccine Market By End Users Age, 2020-2030, USD (Million)
Companies Mentioned
- Beijing Minhai Biotechnology
- CSL Limited
- Dynavax Technologies
- Emergent Biosolutions
- GlaxoSmithKline Biologicals
- Merck & Co Inc.
- Novartis AG
- Pfizer Inc.
- Sanofi Pasteur
- Serum Institute of India
- Sinovac Biotech
